Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Oral & Dental

Assessing the Cost-Effectiveness of Photobiomodulation for Oral Mucositis Prevention and Treatment: A Systematic Review

PBM is a cost-effective long-term treatment, effective in preventing severe OM and improving the quality of life of cancer patients. More RCTs following the same standardized protocols are needed (registration CDR42024498825).

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors reviewed three randomized controlled trials involving 229 head and neck cancer patients receiving chemotherapy or radiotherapy, comparing photobiomodulation with placebo. They report that photobiomodulation may add short-term cost but may be less costly over the medium to long term, and that the treatment group had a lower incidence of severe oral mucositis. The certainty of evidence was rated moderate, and the authors call for more trials using standardized protocols.

Participants
229
Studies included
3
Who or what was studied
Patients with head and neck cancer undergoing chemotherapy and/or radiotherapy
Limits stated in the abstract
Only three randomized trials were included, the certainty of evidence was rated moderate, and the authors state more trials following standardized protocols are needed.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

We report on the cost-effectiveness of photobiomodulation (PBM) for the prevention and treatment of oral mucositis (OM) derived from the cytotoxic effects of antineoplastic therapy.

Methods

This review followed the PRISMA 2020 guidelines. A search was conducted in PubMed, Scopus, Web of Science, Embase, and OpenGrey. Articles published before 23 July 2024, were included. Randomized controlled trials (RCTs) that included patients with head and neck cancer undergoing chemotherapy and/or radiotherapy and a placebo group compared to an intervention group (PBM) were selected. The risk of bias was evaluated using the Joanna Briggs Institute tools. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and was rated as moderate.

Results

A total of 3 RCTs and 229 patients were included. PBM may represent an additional cost in the short term, but the incremental expenses derived from the cytotoxic effects of antineoplastic therapy are greater in the medium-long term. The intervention group (PBM) showed a lower incidence of severe OM compared to the control group (placebo).

Conclusions

PBM is a cost-effective long-term treatment, effective in preventing severe OM and improving the quality of life of cancer patients. More RCTs following the same standardized protocols are needed (registration CDR42024498825).

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a review: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation, Oral mucositis, Systematic review, Control group, Risk of bias, GRADE. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies

Oral & Dental

Evaluation of the effectiveness of repeated piezocision versus repeated low-level laser therapy in the acceleration of upper canine retraction in terms of dentoalveolar and periodontal changes: A three-arm randomized controlled clinical trial

While both repeated piezocision and LLLT accelerate upper canine retraction during the initial three months without harming periodontal health, piezocision seems to be more effective than LLLT in speed and time reduction.

Study · November 18, 2026 · Alfailany DT et al.